Search Results

Displaying: 25 / 100 / 200 results

Ordered by: Date (newest first) / Date (oldest first)

Biogen to develop gene therapies with AGTC

29 July 2015 Business

$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases

Hikma boosts generics with Roxane buyout

29 July 2015 Business

Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market

Celgene to buy immune-inflammatory specialist Receptos

29 July 2015 Business

$7.2bn deal further strengthens Celgene’s position in immunology

Allergan steps away from generics with sale to Teva

29 July 2015 Business

$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top 10

Three dead in Chinese petrochemical plant fire

27 July 2015 Business

Further four workers injured after leaking oil ignited at Qingyang Petrochemical plant in Gansu province

US regulator says DuPont’s safety programme ‘failed’

24 July 2015 Business

The US Occupational Safety and Health Administration has again proposed to fine DuPont after uncovering ‘repeated’ and ‘serious’ lapses in the company’s worker safety programme

Chemical firms seek better grasp of biomanufacturing

23 July 2015 Business

The search is on for better alternatives to the ‘broken’ way companies harness compound-making organisms

An unsustainable hypocrisy

21 July 2015 Business

Social responsibility should extend through the whole supply chain, not just be a tool to put pressure on feedstock suppliers

US import ban imposed on Indian pharma firm

16 July 2015 Business

Concerns over manufacturing processes at Emcure facility prompts Food and Drug Administration to block drug shipments

US chemical maker Platform expands with Alent purchase

15 July 2015 Business

Platform Specialty Products plans to enlarge its scope and reach by acquiring British chemicals firm Alent for $2.1bn

Thermo Fisher to buy Alfa Aesar chemical supplies

8 July 2015 Business

Research chemicals business no longer a strategic fit for owner Johnson Matthey

Celgene backs immunotherapy with Juno collaboration

8 July 2015 Business

$1bn investment in 10-year CAR-T cell partnership for cancer treatments

Blast kills six at South Korean chemical plant

7 July 2015 Business

One further worker injured as tank explodes during welding work

Job cuts at Allergan and Transgene

3 July 2015 Business

Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs

Pharma queues up for checkpoint inhibitor collaborations

3 July 2015 Business

Combinations of different firms’ drugs seek to reap immuno-oncology’s benefits

Fracking prohibited in New York state and Lancashire

2 July 2015 Business

Local US and UK rulings prohibit shale oil drilling and exploration

Allergan to buy Kythera Biopharma for $2.1bn

24 June 2015 Business

Acquisition strengthens firm's position in cosmetic treatments with only drug approved for a 'double chin'

Safer substitutes show growth potential

22 June 2015 Business

The global market for alternative products based on ‘green’ chemistry is growing fast, fuelled by regulation and consumer demand

Alnylam accuses Dicerna of stealing trade secrets

19 June 2015 Business

Firm claims rights to GalNAc conjugated siRNA technology acquired from Merck & Co

Suspect suicide won’t end trade secret theft probe

11 June 2015 Business

An ex-PPG chemist who was arrested for selling trade secrets to a Chinese firm has killed himself, but the Justice Department will continue its investigation

Companies clamour for CAR-T

11 June 2015 Business

Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field

Opko deepens diagnostics with $1.5bn lab buyout

9 June 2015 Business

Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests

Vertex nabs rights to cystic fibrosis molecules

9 June 2015 Business

Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs

BMS sues executive for joining rival company

5 June 2015 Business

Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry

Takeda to consolidate vaccines business in Boston

4 June 2015 Business

Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts